RxDoctor Payments Data

Heather Stehr

Family · Sioux City, IANPI 1295217529

Payments from drug & device makers

$646in general payments, 2019–2025

Across 19 payments — averaging $33.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$438
  • Astellas Pharma US Inc$46
  • Abbott$40
  • Novo Nordisk$29
  • Biohaven Pharmaceutical Holding Company Ltd.$18
  • Grifols USA, LLC$17
  • plus $58 from 4 others

What the payments were for

  • Food & beverage$646100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$646 in reported general payments places this provider in the 70th percentile of 1,268 family providers in Iowa.

See all family providers in Iowa

Medicare billing

Part B allowed, 2024
$1,511
Medicare patients
19
Services billed
88

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala39$148,435
DovatoDolutegravir Sodium/Lamivudine25$73,006
GenvoyaElviteg/Cob/Emtri/Tenof Alafen12$47,007
OdefseyEmtricitab/Rilpiviri/Tenof Ala11$37,464
Trelegy ElliptaFluticasone/Umeclidin/Vilanter51$36,182
EliquisApixaban44$29,195
TrulicityDulaglutide27$28,030
Tresiba Flextouch U-200Insulin Degludec27$25,822
OzempicSemaglutide23$22,020
FarxigaDapagliflozin Propanediol49$21,049
PifeltroDoravirine12$19,861
MounjaroTirzepatide18$18,538
JanuviaSitagliptin Phosphate21$15,989
ShingrixVaricella-Zoster Ge/As01b/Pf56$10,972
RybelsusSemaglutide11$9,739

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya$438$195,44151 claims
Viiv Healthcare CompanyDovato$14$73,00625 claims
Novo NordiskOzempic, Rybelsus$29$31,75934 claims
AbbVieSavella$17$5,88813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,268 family providers in Iowa.

Other family in Sioux City

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →